Get the Stockscreener App
0.3189
3.91%
0.012
Co Diagnostics Inc stock is traded at $0.3189, with a volume of 1.25M.
It is up +3.91% in the last 24 hours and up +8.32% over the past month.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
See More
Previous Close:
$0.3069
Open:
$0.3069
24h Volume:
1.25M
Relative Volume:
0.58
Market Cap:
$10.71M
Revenue:
$7.11M
Net Income/Loss:
$-41.28M
P/E Ratio:
-0.2311
EPS:
-1.38
Net Cash Flow:
$-26.84M
1W Performance:
+8.40%
1M Performance:
+8.32%
6M Performance:
-54.77%
1Y Performance:
-79.43%
1-Day Range:
$0.2951
$0.335
1-Week Range:
$0.2717
$0.3497
52-Week Range:
$0.2275
$2.2299
Co Diagnostics Inc Stock (CODX) Company Profile
Name
Co Diagnostics Inc
Sector
Industry
Phone
(801) 278-9769
Address
4049 SOUTH HIGHLAND DRIVE, SALT LAKE CITY
Compare CODX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CODX
Co Diagnostics Inc
|
0.3189 | 10.79M | 7.11M | -41.28M | -26.84M | -1.38 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Co Diagnostics Inc Stock (CODX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-22 | Downgrade | Sidoti | Buy → Neutral |
| Dec-29-21 | Initiated | Sidoti | Buy |
| Mar-29-21 | Downgrade | Maxim Group | Buy → Hold |
| May-20-20 | Upgrade | Maxim Group | Hold → Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Downgrade | Maxim Group | Buy → Hold |
View All
Co Diagnostics Inc Stock (CODX) Latest News
Historical volatility pattern of Co Diagnostics Inc. visualized2025 Short Interest & Community Trade Idea Sharing - Newser
Co-Diagnostics, Inc. (NASDAQ:CODX) Short Interest Down 29.3% in July - Defense World
News impact scoring models applied to Co Diagnostics Inc.Swing Trade & Fast Gain Stock Tips - Newser
Will breakout in Co Diagnostics Inc. lead to full recovery2025 Growth vs Value & Reliable Breakout Forecasts - Newser
How to build a custom watchlist for Co Diagnostics Inc.Market Trend Summary & Reliable Volume Spike Trade Alerts - Newser
Using flow based indicators on Co Diagnostics Inc.Fed Meeting & High Accuracy Swing Entry Alerts - Newser
Published on: 2025-08-19 16:25:23 - Newser
Multi asset correlation models including Co Diagnostics Inc.Weekly Earnings Recap & Low Risk Investment Opportunities - Newser
Co-Diagnostics stock rating reiterated as Neutral by H.C. Wainwright - Investing.com
Co-Diagnostics Sales Plunge 93 Percent - AOL.com
Co-Diagnostics to Showcase Logix Smart and Co-Dx PCR at Next Generation Dx Summit in D.C. - AInvest
When is the best time to buy Co Diagnostics Inc. stockShort Setup & Capital Efficient Trade Techniques - Newser
Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C. - BioSpace
Co-Diagnostics To Showcase Advancements At Seventeenth Next Generation Dx Summit In Washington, D.C., US: A Step Towards Enhanced Diagnostics For Medical Tourists - Travel And Tour World
Leading Molecular Diagnostics Firm Co-Diagnostics Unveils Next-Gen PCR Platform at Major Summit - Stock Titan
Co-Diagnostics Q2 2025 net loss hits USD 7.7 million - Medical Buyer
Co-Diagnostics Q2 Earnings Miss: Market Impact and Outlook Amid Weak Performance - AInvest
Reviewing Bausch + Lomb (NYSE:BLCO) & Co-Diagnostics (NASDAQ:CODX) - Defense World
What indicators show strength in Co Diagnostics Inc.2025 Support & Resistance & Capital Protection Trading Alerts - Newser
Trend analysis for Co Diagnostics Inc. this weekJuly 2025 Drop Watch & Daily Profit Maximizing Trade Tips - Newser
Co-Diagnostics Q2 Earnings Miss: Market Impact and Recovery Signals - AInvest
Co-Diagnostics (NASDAQ:CODX) Earns “Buy” Rating from D. Boral Capital - Defense World
Co Diagnostics Inc. stock daily chart insightsTrade Entry Report & Reliable Price Action Trade Plans - Newser
Using data tools to time your Co Diagnostics Inc. exit2025 Historical Comparison & Momentum Based Trading Signals - Newser
D. Boral Capital Reaffirms Buy Rating for Co-Diagnostics Stock with $10.00 Price Target - AInvest
Co-Diagnostics Inc Reports Q2 2025 Earnings: EPS Loss of $0.23 Beats Estimates, Revenue at $0.2 Million Surpasses Expectations. - AInvest
Co-Diagnostics: A Pre-Revenue Biotech with a Clear Path to Commercialization and Strong Balance Sheet - AInvest
Co-Diagnostics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Co-Diagnostics, Inc. (NASDAQ:CODX) Q2 2025 Earnings Call Transcript - Insider Monkey
Is Now a Good Time to Reenter Co Diagnostics Inc.2025 Stock Rankings & Reliable Entry Point Alerts - 선데이타임즈
How to escape a deep drawdown in Co Diagnostics Inc.Market Risk Report & Fast Moving Stock Watchlists - Newser
RSI and MACD Indicate Shift in Co Diagnostics Inc. SentimentPortfolio Gains Report & Community Shared Stock Ideas - 선데이타임즈
Will Co Diagnostics Inc. stock go up soonWeekly Investment Recap & Smart Money Movement Tracker - Newser
Camp4 Reports Q2 Revenue Beats Estimates - AOL.com
CODX.O: Sharp Intraday Surge Without Clear Fundamental Catalyst - AInvest
Co-Diagnostics (CODX) Surges 15.7% on Unusual Intraday Volatility—What’s Fueling the Surge? - AInvest
Co-Diagnostics, Inc. shares rise 16.23% intraday after Q2 2025 earnings call. - AInvest
When is the best time to exit Co Diagnostics Inc.Entry Point & Free AI Powered Buy and Sell Recommendations - Newser
CODX.O Surges 37.5%—But No Fundamental News—Technical Clues and Order-Flow Hints Point to Institutional Involvement - AInvest
Co-Diagnostics Soars 27% on Earnings Optimism and Regulatory Momentum - AInvest
Co-Diagnostics Inc Reports Q2 2025 Earnings: EPS Loss of $0.23 Beats Estimates, Revenue at $0.2 Million Surpasses Expectations - GuruFocus
Co-Diagnostics outlines clinical trial timeline and targets mid-2026 commercialization for PCR platform - MSN
Understanding Co Diagnostics Inc.’s price movementWeekly Profit Report & AI Powered Buy/Sell Recommendations - Newser
Co-Diagnostics: Boral Capital Raises PT to $10, Maintains Buy Rating - AInvest
Ranking Co Diagnostics Inc. among high performing stocks via toolsTrade Risk Summary & Community Shared Stock Ideas - Newser
Co-Diagnostics Inc (CODX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results - BioSpace
bioAffinity Misses Q2 Revenue Target - AOL.com
Co-Diagnostics Reports Q2 2025 Financial Results - TipRanks
Co-Diagnostics Q2 rev down 92.6% to $0.2mln, op expenses down 19.1% YoY. - AInvest
Co-Diagnostics Progresses PCR Platform Clinical Trials, Targets Mid-2026 Commercialization. - AInvest
Co Diagnostics Inc Stock (CODX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):